FDAers Sink Mevacor OTC At Panel Meeting With Unflinching Critique

Presentations by FDA OTC division cast Johnson & Johnson/Merck Mevacor OTC studies in negative light during advisory committee meeting. FDAers cite low rates of proper self-selection, comprehension for CUSTOM actual-use study.